K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · REGENERON PHARMACEUTICALS INC
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $640K | Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations. Tax and inflation issues related to corporations. |
| 2026-01-20 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $610K | Tax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations. |
| 2025-10-20 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $570K | Trade and tariff issues related to corporations. Tax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. |
| 2025-07-21 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $610K | Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations. Tax and inflation issues related to corporations. |
| 2025-04-21 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $400K | Tax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; National Defense Authorization Act; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations. |
| 2025-01-21 | REGN | REGENERON PHARMACEUTICALS INC | REGENERON PHARMACEUTICALS, INC | $400K | Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; Tax and incentives; Issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; Issues relating to pandemic preparedness and infectious disease education; Issues relating to utilization management; Issues relating to health care extenders; Issues related to federal contracting relating to biopharmaceutical manufacturers Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers Patent issues relating to biopharmaceutical manufacturers; Intellectual property rights; Issues relating to WTO TRIPS waivers |